Basit öğe kaydını göster

dc.contributor.authorErtürk, U. S.
dc.contributor.authorMete, Birgül
dc.contributor.authorÖzaras, Reşat
dc.contributor.authorSaltoğlu, Neşe
dc.contributor.authorBalkan, I. I.
dc.contributor.authorMert, Ali
dc.contributor.authorKaçmaz, Bahar
dc.contributor.authorSağlam, Onursal
dc.contributor.authorGüney, B.
dc.contributor.authorSayman, O. A.
dc.contributor.authorTabak, Fehmi
dc.date.accessioned2021-10-04T07:16:38Z
dc.date.available2021-10-04T07:16:38Z
dc.date.issued2021en_US
dc.identifier.citationErtürk, U. S., Mete, B., Özaras, R., Saltoğlu, N., Balkan, I. I., Mert, A. ... Tabak, F. (2021). Plasma and breast milk pharmacokinetics of tenofovir disoproxil fumarate in nursing mother with chronic hepatitis B-infant pairs. Antimicrobial Agents and Chemotherapy, 65(10). https://dx.doi.org/10.1128/AAC.01110-21en_US
dc.identifier.issn0066-4804
dc.identifier.issn1098-6596
dc.identifier.urihttps://dx.doi.org/10.1128/AAC.01110-21
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8347
dc.description.abstractTenofovir use is associated with lower risk of mother-to-infant transmission of the virus, and discontinuation of the treatment is not safe. However, the safety of the drug during pregnancy and breastfeeding is not clear. In this study, we aimed to determine the tenofovir concentration in plasma of mother-infant pairs along with breast milk in chronic hepatitis B patients during the lactation period. A total of 11 mother-infant pairs were enrolled in the study. All the mothers received tenofovir disoproxil fumarate (TDF) 245mg/day for at least 1 month because of chronic hepatitis B infection. Maternal blood, breast milk, and infant blood samples were obtained concomitantly. Tenofovir concentrations were determined by liquid chromatography-tandem mass spectrometry. The median concentrations of tenofovir in maternal plasma and breast milk samples were 88.44 (interquartile range [IQR], 62.47 to 116.17) ng/ml and 6.69 (IQR, 4.88 to 7.03) ng/ml, respectively. Tenofovir concentrations were undetectable (,4ng/ml) in all of the infant plasma samples. The ratio of tenofovir concentration in breast milk to that in maternal plasma was 0.07. Tenofovir disoproxil fumarate passes through the breast milk in a small amount. Infants had no detectable tenofovir level in their plasma. Our study suggests that tenofovir disoproxil fumarate treatment is safe during the breastfeeding period in chronic hepatitis B patients.en_US
dc.description.sponsorshipViral Hepatitis Society ; Istanbul Universityen_US
dc.language.isoengen_US
dc.publisherAmerican Society for Microbiologyen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Milken_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectInfant Plasmaen_US
dc.subjectTenofoviren_US
dc.titlePlasma and breast milk pharmacokinetics of tenofovir disoproxil fumarate in nursing mother with chronic hepatitis B-infant pairsen_US
dc.typearticleen_US
dc.relation.ispartofAntimicrobial Agents and Chemotherapyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.authorid0000-0001-8945-2385en_US
dc.identifier.volume65en_US
dc.identifier.issue10en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1128/AAC.01110-21en_US
dc.identifier.wosqualityQ1en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster